Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.
Pfister D, Oechsle K, Schmidt S, Busch J, Bokemeyer C, Heidenreich A, Heinzelbecker J, Ruf C, Winter C, Zengerling F, Kliesch S, Albers P, Oing C. Pfister D, et al. Among authors: oechsle k. World J Urol. 2022 Dec;40(12):2853-2861. doi: 10.1007/s00345-022-03959-8. Epub 2022 Feb 28. World J Urol. 2022. PMID: 35226138 Free PMC article. Review.
Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, Kanz L, Bokemeyer C. Kollmannsberger C, et al. Among authors: oechsle k. Cancer. 2002 May 1;94(9):2353-62. doi: 10.1002/cncr.10494. Cancer. 2002. PMID: 12015760 Free article.
The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, Hartmann JT, Vonthein R, Claussen CD. Pfannenberg AC, et al. Among authors: oechsle k. World J Urol. 2004 Jun;22(2):132-9. doi: 10.1007/s00345-003-0392-6. Epub 2004 Jan 21. World J Urol. 2004. PMID: 14735310
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. Kollmannsberger C, et al. Among authors: oechsle k. Ann Oncol. 2006 Jun;17(6):1007-13. doi: 10.1093/annonc/mdl042. Epub 2006 Mar 13. Ann Oncol. 2006. PMID: 16533873 Free article. Clinical Trial.
142 results